Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 24.79% year-on-year.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD 44.36M.%!(EXTRA int=2)
Undervalued
The company’s latest PE is -6.04, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 27.35M shares, decreasing 9.34% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.61M shares of this stock.